We develop, license, and sell pharmaceutical products in Australasia & around the world. Our commitment to innovation makes a real difference to health.
Location: New Zealand, Auckland
Employees: 51-200
Phone: +64 800 423 823
Founded date: 1997
Investors 1
Mentions in press and media 11
| Date | Title | Description |
| 15.06.2026 | Stablepharma and AFT Move to Expand Fridge-Free Vaccine Distribution Following Positive Clinical Data | Stablepharma, specialists in thermostable formulations, signed LOI with AFT for distribution of SPVX02, a fridge-free Td vaccine, in UK, Canada, Australia & NZ With AFT Pharmaceuticals, we are working to translate our fridge-free innova... |
| 18.11.2021 | AFT Pharmaceuticals : 211118 AFT 1H FY22 Market ReleaseOpens in a new Window | Market release 18 November 2021 UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2021 AFT reaffirms guidance and progresses growth plan HIGHLIGHTS* Revenue rises 14% to $55.5 million from $48.8 million despite multiple COVID-19... |
| 17.11.2021 | AFT Pharmaceuticals : 211118 AFT 1H FY22 Market Release | For personal use only Market release 18 November 2021 UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2021 AFT reaffirms guidance and progresses growth plan HIGHLIGHTS* Revenue rises 14% to $55.5 million from $48.8 million des... |
| 18.10.2021 | AFT Launches NZ-Made, 100% Natural, 90% Recyclable Hemptuary® Skincare Range | SYDNEY, Oct. 18, 2021 /PRNewswire/ -- Skincare mavens and beauty gurus have a new product to not only feel good in but feel good about – AFT Pharmaceuticals' new skincare range, Hemptuary®, is made in New Zealand from 100% natural ingredien... |
| 13.07.2021 | GENERAL: AFT: Maxigesic® Oral Liquid gets first regulatory approvalOpens in a new Window | 14 July 2021 Maxigesic® Oral Liquid gets first regulatory approval Maxigesic Oral Liquid - a non-opioid analgesic developed for children - achieves first approval in Europe to set up the first global launch and a pathway for further registr... |
| 08.07.2021 | GENERAL: AFT: Maxigesic® IV launches in Germany and AustriaOpens in a new Window | 8th July 2021 Maxigesic® IV launches in Germany and Austria Commercialisation of Maxigesic IV in Europe is progressing well with launches and further registrations. AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces its licensee Ever ... |
| 24.05.2021 | AFT PHARMACEUTICALS LIMITED AFT Pharmaceuticals : FY2021 AnnouncementOpens in a new Window | 24 May 2021 AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2021 AFT delivers growth amid global disruptions HIGHLIGHTS Revenue reaches a new record of $113.1 million, up 7% from the $105.6 million in the prior year, despite Covid-19 dis... |
| 28.04.2021 | AFT PHARMACEUTICALS LIMITED GENERAL: AFT: AFT licenses Maxigesic® IV in the USOpens in a new Window | 28 April 2021 AFT licenses Maxigesic® IV in the US Agreement with Hikma, the US' third largest supplier of generic injectable medications by volume1, will see AFT benefit from upfront, regulatory and commercial milestone payments worth up t... |
| 12.04.2021 | AFT PHARMACEUTICALS LIMITED AFT Pharmaceuticals : Crystawash Extend distribution in UAE, Kuwait, Oman and KenOpens in a new Window | 12 April 2021 Crystawash® Extend distribution in UAE, Kuwait, Oman and Kenya. AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed agreements to distribute its long-acting hand sanitiser Crystawash® Extend in the United Arab... |
| 06.04.2021 | AFT PHARMACEUTICALS LIMITED GENERAL: AFT: AFT secures new partners in Poland and Greece Opens in a new Window | 7 April 2021 AFT secures new partners in Poland and Greece AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces an extension to its Maxigesic® commercialisation agreements, adding the Polish Company Mercapharm Sp.z.o.o ('Mercapharm') and ... |
Show more